NCT Number: NCT07093892
Cohort Study on Cognitive Decline in Elderly
Alzheimer's Disease (AD) prevention and control currently face severe challenges, with limited treatment options and effectiveness available. Once the disease progresses to the AD stage, it is essentially irreversible. Before the onset of AD, there is a prolonged asymptomatic period and a stage of mild cognitive impairment (MCI), which represents a critical window for early screening, diagnosis, and intervention. Therefore, early screening, diagnosis, and intervention during the MCI stage are crucial for slowing or halting the rising trend of AD and alleviating its disease burden.
This study plans to enroll elderly individuals from communities around Peking University Third Hospital to establish a prospective cohort. Participants will undergo cognitive assessments and blood biomarker testing, followed by a three-year follow-up and management program. The study aims to obtain epidemiological data on MCI and AD in community populations, investigate the relationships between known risk factors, genetic factors, and blood biomarkers with disease progression, explore additional biomarkers, and develop predictive models. These efforts will contribute to promoting early diagnosis, early intervention, and improved prognosis.
Trial opening soon.
Get NotifiedKey information
Age range
55 year and older
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Aged 55 years or older;
- No diagnosis of Alzheimer's disease (AD);
- Participants are able to complete cognitive tests, provide biological samples, undergo neuroimaging examinations, and cooperate throughout the entire study process;
- Signed informed consent.
Exclusion criteria
- Participants with severe mental illness, tumor-related cachexia, severe hepatic or renal insufficiency, or other major physical conditions that may hinder cooperation with the examinations;
- Participants who are unable to complete the required assessments due to visual or hearing impairments;
- Contraindications for MRI or other study-related examinations.
Treatment and study plan
Primary outcomes
-
The change of MMSE
Time frame: 3 years
MMSE is a 30-point questionnaire used to measure cognitive function
-
The change of MoCA
Time frame: 3 years
MoCA is a 30-point questionnaire used to measure cognitive function
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Peking University Third Hospital
Other
Registry information
Important dates
- Study start
- 2025
- Primary completion
- 2028
- Study completion
- 2028
- First posted
- Jul 30, 2025
- Registry last updated
- Jul 30, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.